Evidence map›Paper›PMID 41155621›Full record

ArticlePharmaceuticals (Basel, Switzerland)2025

Cannabigerol Modulates Cannabinoid Receptor Type 2 Expression in the Spinal Dorsal Horn and Attenuates Neuropathic Pain Models.

Bismarck Rezende, Gabriel Gripp Fernandes, Vitória Macario de Simas Gonçalves, Gabriela Guedes Nascimento, Kethely Lima Marques, Barbara Conceição Costa Azeredo de Oliveira, Yure Bazilio Dos Santos, Maria Eduarda Barros de Andrade, Karine Simões Calumbi, Eduardo Perdigão Maia and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Bismarck RezendeDepartment of Pharmacology and Psychobiology, Roberto Alcantara Gomes Biology Institute (IBRAG), Rio de Janeiro State University (UERJ), Rio de Janeiro 20551-030, Brazil.ORCID 0000-0002-4005-6493
Gabriel Gripp FernandesNeuroPharmacoGenetics Laboratory, Department of Pharmacology and Psychobiology, Rio de Janeiro State University (UERJ), Rio de Janeiro 20551-030, Brazil.
Vitória Macario de Simas GonçalvesDepartment of Pharmacology and Psychobiology, Roberto Alcantara Gomes Biology Institute (IBRAG), Rio de Janeiro State University (UERJ), Rio de Janeiro 20551-030, Brazil.
Gabriela Guedes NascimentoDepartment of Pharmacology and Psychobiology, Roberto Alcantara Gomes Biology Institute (IBRAG), Rio de Janeiro State University (UERJ), Rio de Janeiro 20551-030, Brazil.
Kethely Lima MarquesDepartment of Pharmacology and Psychobiology, Roberto Alcantara Gomes Biology Institute (IBRAG), Rio de Janeiro State University (UERJ), Rio de Janeiro 20551-030, Brazil.
Barbara Conceição Costa Azeredo de OliveiraDepartment of Pharmacology and Psychobiology, Roberto Alcantara Gomes Biology Institute (IBRAG), Rio de Janeiro State University (UERJ), Rio de Janeiro 20551-030, Brazil.
Yure Bazilio Dos SantosDepartment of Pharmacology and Psychobiology, Roberto Alcantara Gomes Biology Institute (IBRAG), Rio de Janeiro State University (UERJ), Rio de Janeiro 20551-030, Brazil.
Maria Eduarda Barros de AndradeDepartment of Pharmacology and Psychobiology, Roberto Alcantara Gomes Biology Institute (IBRAG), Rio de Janeiro State University (UERJ), Rio de Janeiro 20551-030, Brazil.
Karine Simões CalumbiDepartment of Pharmacology and Psychobiology, Roberto Alcantara Gomes Biology Institute (IBRAG), Rio de Janeiro State University (UERJ), Rio de Janeiro 20551-030, Brazil.
Eduardo Perdigão MaiaDepartment of Pharmacology and Psychobiology, Roberto Alcantara Gomes Biology Institute (IBRAG), Rio de Janeiro State University (UERJ), Rio de Janeiro 20551-030, Brazil.
Luisa Menezes TrefilioDepartment of Pharmacology and Psychobiology, Roberto Alcantara Gomes Biology Institute (IBRAG), Rio de Janeiro State University (UERJ), Rio de Janeiro 20551-030, Brazil.
Fernanda AntunesAnimal Clinic and Surgery Laboratory, Center for Agricultural Sciences and Technologies (CCTA), State University of Northern Fluminense Darcy Ribeiro (UENF), Campos dos Goytacazes 28013-602, Brazil.
Fabrícia Lima Fontes-DantasDepartment of Pharmacology and Psychobiology, Roberto Alcantara Gomes Biology Institute (IBRAG), Rio de Janeiro State University (UERJ), Rio de Janeiro 20551-030, Brazil.
Guilherme Carneiro MontesDepartment of Pharmacology and Psychobiology, Roberto Alcantara Gomes Biology Institute (IBRAG), Rio de Janeiro State University (UERJ), Rio de Janeiro 20551-030, Brazil.ORCID 0000-0003-4946-9056

Funding

CNPq 444648/2023-2FAPERJ E17-200.197/2025; 200.198/2025FAPERJ E-26/204.419/2023FAPERJ E-26/210.559/2025FAPERJ SEI-260003/006158/2024; SEI-260003/013218/2024Parliamentary Amendment No. 491/2024
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cannabigerolcannabinoid receptor type 2 (CB2R)cannabischronic painpain

Identifiers

PMID41155621
PMCPMC12567403

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.